Hologic, Inc. (HOLX)

Market Cap	16.28B
Revenue (ttm)	4.03B
Net Income (ttm)	789.50M
Shares Out	225.72M
EPS (ttm)	3.32
PE Ratio	21.73
Forward PE	16.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,595,137
Open	71.81
Previous Close	72.17
Day's Range	71.81 - 72.73
52-Week Range	68.61 - 84.67
Beta	0.98
Analysts	Buy
Price Target	88.92 (+23.26%)
Earnings Date	Feb 5, 2025

About HOLX

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginos...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jun 21, 1990
• Employees: 6,990
• Stock Exchange: NASDAQ
• Ticker Symbol: HOLX
• Website: https://www.hologic.com

Financial Performance

In 2024, Hologic's revenue was $4.03 billion, a decrease of -0.00% compared to the previous year's $4.03 billion. Earnings were $789.50 million, an increase of 73.14%.

Analyst Forecast

According to 14 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price forecast is $88.92, which is an increase of 23.26% from the latest price.

Price Target

$88.92

(23.26% upside)

Analyst Consensus: Buy